Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 1/20 | 0.36 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
| ▸ | JAK2 | O60674 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PFKFB3 | Q16875 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 2/20 | 0.33 |
| ▸ | MAP3K6 | O95382 | 1/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL984729 | 1.00 | MDM4 (0.36) | MDM4CCNT1CDK9SCN9AJAK3 | |
| SCHEMBL982924 | 0.97 | MDM4 (0.36) | MDM4CCNT1CDK9SCN9AJAK3 | |
| SCHEMBL981875 | 0.96 | MDM4 (0.39) | MDM4CCNT1CDK9LRRK2PIK3CA | |
| SCHEMBL984636 | 0.93 | PIK3CD (0.37) | MDM4SCN9AJAK3POLBPIK3CA | |
| SCHEMBL983553 | 0.93 | PIK3CD (0.37) | MDM4SCN9AJAK3POLBPIK3CA | |
| SCHEMBL984909 | 0.93 | MDM4 (0.39) | MDM4CCNT1CDK9SCN9ALRRK2 | |
| SCHEMBL981629 | 0.92 | POLB (0.39) | MDM4SCN9AJAK3POLBBTK | |
| SCHEMBL984462 | 0.92 | POLB (0.39) | MDM4SCN9AJAK3POLBBTK | |
| SCHEMBL984207 | 0.92 | MDM4 (0.35) | MDM4SCN9AJAK3LRRK2POLB | |
| SCHEMBL984985 | 0.92 | MDM4 (0.35) | MDM4SCN9AJAK3LRRK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | claimed |
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | NYCOMED GMBH (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021479-A1 | PYRROLOPYRIMIDINECARBOXAMIDES | PDE5A, PDE3A, PDE2A | MDM4 2898/4885CCNT1 807/4885CDK9 639/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.